Impact of Epstein-Barr virus infection on inflammatory bowel disease (IBD) clinical outcomes
- 1 January 2021
- journal article
- research article
- Published by Sociedad Espanola de Patologia Digestiva (SEPD) in Revista Española de Enfermedades Digestivas
- Vol. 114 (5) , 259-265
Abstract
Objective: to evaluate the role of Epstein-Barr virus (EBV) on the intestinal mucosa in the evolution of inflammatory bowel disease (IBD). The risk factors for EBV infection and the frequency of EBV-associated lymphoproliferative disorders in IBD patients were also investigated. Methods: intestinal biopsies of IBD patients with available EBV status determined by Epstein-Barr-encoding RNA (EBER) in situ hybridization were identified in the Pathology Database of our center. Clinical information, including phenotypic characteristics of IBD, previous treatments, diagnosis of lymphoma and patient outcome were reviewed in all cases. Results: fifty-six patients with IBD (28 Crohn's disease, 27 ulcerative colitis and one unclassified colitis) were included. EBV in intestinal mucosa was positive in 26 patients (46 %) and was associated to a lymphoproliferative syndrome in one case. EBV positivity was associated with severe histological activity (52 % vs 17.2 %; p 0.007), the presence of a lymphoplasmacytic infiltrate (50 % vs 33.3 %; p 0.03) and active steroid treatment (61.5 % vs 33.3 %; p 0.03). Multi-variate analyses only found an association between EBV and lymphoplasmacytosis (p 0.001). Escalation in previous treatment was significantly more frequent in the EBER+ group (53.8 % vs 26.7 %; p 0.038). No cases developed lymphoma during follow-up. Conclusions: EBV on the intestinal mucosa is associated with a poor outcome of IBD and the need for escalation of therapy. Lymphoplasmacytic infiltrate is associated with EBV infection. EBER+ patients used steroids more frequently compared with EBER- patients. No EBER+ patients developed lymphoma during follow-up.Keywords
This publication has 24 references indexed in Scilit:
- Differential cellular localization of Epstein–Barr virus and human cytomegalovirus in the colonic mucosa of patients with active or quiescent inflammatory bowel diseaseImmunologic Research, 2015
- Anti‐TNFα therapy for inflammatory bowel diseases is associated with Epstein‐Barr virus lytic activationJournal of Medical Virology, 2015
- Epstein–Barr Virus in Inflammatory Bowel Disease: The Spectrum of Intestinal Lymphoproliferative DisordersJournal of Crohn's and Colitis, 2015
- Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disordersWorld Journal of Gastrointestinal Pathophysiology, 2015
- Severe Colitis Associated with both Epstein-Barr Virus and Cytomegalovirus Reactivation in a Patient with Severe Aplastic AnemiaCase Reports in Gastroenterology, 2014
- Inflammatory Bowel Disease Exacerbation Associated With Epstein-Barr Virus InfectionDiseases of the Colon & Rectum, 2013
- Epstein–Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel diseaseJournal of Clinical Virology, 2011
- Distribution and Phenotype of Epstein-Barr Virus-Infected Cells in Inflammatory Bowel DiseaseThe American Journal of Pathology, 2000
- Epstein-Barr Virus–Positive Primary Gastrointestinal Hodgkin's DiseaseAmerican Journal of Surgical Pathology, 2000
- Classification of Inflammatory Bowel DiseaseScandinavian Journal of Gastroenterology, 1989